All In Biotech

Free tool

FAERS Monitor: Xphozah

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 19, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 213931 or its brand name (Xphozah, Tenapanor Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

23

Serious

18

78% of reports

Hospitalization

9

Death reported

0

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • nausea3
  • anaemia2
  • asthenia2
  • cough2
  • covid-192
  • decreased appetite2
  • diarrhoea2
  • drug ineffective2
  • drug ineffective for unapproved indication2
  • fatigue2
  • gastrointestinal disorder2
  • pre-existing condition improved2
  • abdominal discomfort1
  • abdominal pain1
  • abdominal wall haematoma1

Reports by year received

View as table
YearReports
20212
20232
20244
20256
20269

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,136 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
abdominal wall haematoma1469.068.9116
pre-existing condition improved2293.177.9327
drug ineffective for unapproved indication233.38.935
gastrointestinal disorder220.45.420
covid-19210.42.89
anaemia29.62.68
decreased appetite27.92.16
cough26.51.75
abdominal discomfort15.50.81
asthenia24.91.33
abdominal pain13.90.60
nausea33.51.23
diarrhoea22.80.81
fatigue22.30.61
drug ineffective21.40.40

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.